https://www.businesswire.com/news/home/20180530005702/en/

LONDON--(BUSINESS WIRE)--May 31, 2018--UK based bio-pharmaceutical company SiSaf closes a $4.3million interim funding round led by Vickers Venture Partners with additional capital injections by Invest NI and Innovation Ulster Limited.

SiSaf is a young, commercial stage company that develops drugs using bio-courier technology, ProSilic ®, a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes. The company plans to use the investment to accelerate the development of its dermatology pipeline.